青春期因注意缺陷多动障碍使用兴奋剂治疗后,成年早期可卡因或甲基苯丙胺使用情况
该研究基于美国12年级学生全国多队列纵向面板(基线2005-2017年,随访至23-24岁),纳入5034名学生,其中470人(10.2%)报告ADHD兴奋剂治疗,671人(14.6%)仅报告处方兴奋剂误用(PSM),3459人(75.2%)两者均无(人群对照)。控制分析显示,ADHD兴奋剂治疗组与对照组的成年早期可卡因或甲基苯丙胺起始或使用调整比值比无统计学显著差异;而PSM组相比对照组,后续可卡因或甲基苯丙胺起始和使用的调整比值比为2.64(95%CI 1.54-4.55)。作者认为,青少年ADHD兴奋剂治疗与成年早期可卡因和甲基苯丙胺使用风险增加无关,PSM可作为后续可卡因或甲基苯丙胺使用的信号,值得监测和筛查。
要点
- 青少年因ADHD接受兴奋剂治疗与成年早期可卡因或甲基苯丙胺起始或使用风险增加无统计学显著关联。
- 青少年处方兴奋剂误用(PSM)者成年早期可卡因或甲基苯丙胺起始和使用的调整比值比为2.64(95%CI 1.54-4.55)。
- 基线5034名学生中,10.2%(95%CI 9.4%-11.2%)报告ADHD兴奋剂治疗,14.6%(95%CI 13.5%-15.6%)报告仅PSM,75.2%(95%CI 73.9%-76.4%)两者均无。
- 作者认为,PSM提供了后续可卡因或甲基苯丙胺使用的信号,值得监测和筛查。
适用人群与场景
- 美国相邻地区12年级公立和私立学校学生的全国多队列纵向面板,基线队列年份2005-2017年(3月至6月间),随访3波共6年至23-24岁(随访年份2011-2021年,4月至10月间)。
研究设计与关键结果
- 研究类型:全国多队列纵向面板研究;基线纳入5034名学生(2589名[52.0%]女性),随访3波至23-24岁。
- 暴露:基线自我报告的ADHD兴奋剂治疗史;470人(10.2%[95%CI 9.4%-11.2%])报告ADHD兴奋剂治疗,671人(14.6%[95%CI 13.5%-15.6%])报告仅PSM,3459人(75.2%[95%CI 73.9%-76.4%])两者均无(人群对照)。
- 主要结局:成年早期(19-24岁)过去一年可卡因和甲基苯丙胺使用的发病率和患病率。
- 控制分析显示,基线报告ADHD兴奋剂治疗的青少年与人群对照相比,成年早期(19-24岁)过渡到可卡因或甲基苯丙胺起始或使用的调整比值比无统计学显著差异。
- 相比之下,未因ADHD接受兴奋剂治疗的青少年中,青春期PSM与人群对照相比,成年早期过渡到可卡因或甲基苯丙胺起始和使用的调整比值比为2.64(95%CI 1.54-4.55)。
证据类型、等级与局限
- 证据类型:全国多队列纵向面板研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,青少年ADHD兴奋剂治疗与成年早期可卡因和甲基苯丙胺使用风险增加无关。
- 作者认为,青少年PSM提供了后续可卡因或甲基苯丙胺使用的信号,值得监测和筛查。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The prescribing of stimulant medications for attention-deficit/hyperactivity disorder (ADHD) has increased in the US. Prescription stimulants are one of the most commonly misused controlled substances during adolescence. Despite a 10-fold increase in stimulant-related overdose deaths in the past decade, the transitions from prescription stimulants to illicit stimulants (eg, cocaine, methamphetamine) remain relatively unknown in longitudinal population-based studies.
OBJECTIVE: To determine the longitudinal transitions from adolescents' prescription stimulant exposure (ie, stimulant therapy for ADHD and prescription stimulant misuse [PSM]) to later cocaine and methamphetamine use during young adulthood.
DESIGN, SETTING, AND PARTICIPANTS: National longitudinal multicohort panels of US 12th grade public and private school students in the coterminous US were assessed annually (baseline cohort years 2005-2017 [between March and June]) and followed up across 3 waves over a 6-year period to 23 to 24 years of age (follow-up years 2011-2021 [between April and October]).
EXPOSURE: History of self-reported stimulant therapy for ADHD at baseline.
MAIN OUTCOMES AND MEASURES: Incidence and prevalence of past-year use of cocaine and methamphetamine during young adulthood (19-24 years of age).
RESULTS: Among 5034 students enrolled at baseline (2589 [52.0%] female), 470 (10.2% [95% CI, 9.4%-11.2%]) reported use of stimulant therapy for ADHD, 671 (14.6% [95% CI, 13.5%-15.6%]) reported PSM only, and 3459 (75.2% [95% CI, 73.9%-76.4%]) reported neither (and served as population controls). In controlled analyses, there were no statistically significant differences between adolescents who reported stimulant therapy for ADHD at baseline compared with population controls in the adjusted odds of transitioning to later cocaine or methamphetamine initiation or use during young adulthood (19-24 years of age). In contrast, PSM during adolescence in those not treated with stimulants for ADHD had significantly higher odds of transitioning to later cocaine or methamphetamine initiation and use during young adulthood compared with population controls (adjusted odds ratio, 2.64 [95% CI, 1.54-4.55]).
CONCLUSIONS AND RELEVANCE: In this multicohort study, adolescents' stimulant therapy for ADHD was not associated with increased risk of later cocaine and methamphetamine use during young adulthood. Adolescents' prescription stimulant misuse offered a signal for subsequent cocaine or methamphetamine use and warrants monitoring and screening.
参考来源
- McCabe SE, Schulenberg JE, Wilens TE, et al. Cocaine or Methamphetamine Use During Young Adulthood Following Stimulant Use for Attention-Deficit/Hyperactivity Disorder During Adolescence. JAMA Netw Open. 2023. PMID: 37432689. doi:10.1001/jamanetworkopen.2023.22650
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。